Analysis of serum microRNA‐122 in a randomized controlled trial of N‐acetylcysteine for treatment of antituberculosis drug‐induced liver injury

Serum microRNA‐122 (miR‐122) is a novel biomarker for drug‐induced liver injury, with good sensitivity in the early diagnosis of paracetamol‐induced liver injury. We describe miR‐122 concentrations in participants with antituberculosis drug‐induced liver injury (AT‐DILI). We explored the relationship between miR‐122 and alanine aminotransferase (ALT) concentrations and the effect of N‐acetylcysteine (NAC) on miR‐122 concentrations.

• Publication year

  2023

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2023-01-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bcp.15661PMID 36639145PMCID 10952339
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Analysis of serum microRNA‐122 in a randomized controlled trial of N‐acetylcysteine for treatment of antituberculosis drug‐induced liver injury

  2023cited by this paper
• MicroRNA‐122 and cytokeratin‐18 have potential as a biomarkers of drug‐induced liver injury in European and African patients on treatment for mycobacterial infection

  2021cited by this paper
• Altered expressions of circulating microRNAs 122 and 192 during antitubercular drug induced liver injury indicating their role as potential biomarkers

  2021cited by this paper
• A Randomized Controlled Trial of Intravenous N-acetylcysteine in the Management of Anti-tuberculosis Drug-Induced Liver Injury.

  2020cited by this paper
• A novel microRNA signature for cholestatic drugs in human hepatocytes and its translation into novel circulating biomarkers for drug-induced liver injury patients.

  2019cited by this paper
• Variance component analysis of circulating miR-122 in serum from healthy human volunteers

  2019cited by this paper
• Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: An international collaborative effort

  2018cited by this paper
• Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance

  2017cited by this paper
• Mechanism of isoniazid‐induced hepatotoxicity: then and now

  2016cited by this paper
• Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-induced liver injury.

  2015cited by this paper
• Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury

  2015cited by this paper
• Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis

  2014cited by this paper
• Keratin‐18 and microRNA‐122 complement alanine aminotransferase as novel safety biomarkers for drug‐induced liver injury in two human cohorts

  2014cited by this paper
• Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital

  2013cited by this paper
• miRBase: annotating high confidence microRNAs using deep sequencing data

  2013cited by this paper
• MicroRNAs in liver disease

  2013cited by this paper
• Serum levels of microRNAs can specifically predict liver injury of chronic hepatitis B.

  2012cited by this paper
• Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug‐induced, and inflammatory liver diseases

  2012cited by this paper
• Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver.

  2012cited by this paper
• MicroRNAs in liver disease.

  2012cited by this paper
• Circulating microRNAs as potential markers of human drug‐induced liver injury

  2011cited by this paper
• Circulating MicroRNAs, miR‐21, miR‐122, and miR‐223, in patients with hepatocellular carcinoma or chronic hepatitis

  2011cited by this paper
• Circulating microRNAs, potential biomarkers for drug-induced liver injury

  2009cited by this paper
• Antituberculosis drug‐induced hepatotoxicity: Concise up‐to‐date review

  2008cited by this paper
• Isoforms of alanine aminotransferases in human tissues and serum--differential tissue expression using novel antibodies.

  2007cited by this paper
• American Thoracic Society Documents An Official ATS Statement : Hepatotoxicity of Antituberculosis Therapy

  2006cited by this paper
• miR-122, a Mammalian Liver-Specific microRNA, is Processed from hcr mRNA and MayDownregulate the High Affinity Cationic Amino Acid Transporter CAT-1

  2004cited by this paper
• Intensified Cloning Efforts Have Revealed Numer

  2004cited by this paper

• Anti‐Tubercular Drug‐Induced Liver Injury: Current Understanding and Emerging Directions

  2026cites this paper
• Extrahepatic and Circulating miR-122: Diagnostic Implications and Future Directions.

  2025cites this paper
• Biomarkers for the prediction and monitoring of the antipsychotic/antidepressant-induced hepatotoxicity: study protocol

  2025cites this paper
• Drug Induced Liver Injury: Highlights and Controversies in the 2023 Literature

  2025cites this paper
• Genetic polymorphisms and adverse reactions to antituberculosis therapy

  2025cites this paper
• Serum Levels of miR-122-5p and miR-125a-5p Predict Hepatotoxicity Occurrence in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation

  2024cites this paper
• Novel miRNA biomarkers for alveolar echinococcosis: sequencing and clinical validation

  2024cites this paper
• Analysis of serum microRNA‐122 in a randomized controlled trial of N‐acetylcysteine for treatment of antituberculosis drug‐induced liver injury

  2023cites this paper
• The role of miRNAs in liver diseases: Potential therapeutic and clinical applications.

  2023cites this paper
• The emerging role of miRNA-122 in infectious diseases: Mechanisms and potential biomarkers.

  2023cites this paper